<DOC>
	<DOCNO>NCT00560573</DOCNO>
	<brief_summary>CP 751,871 fully human monoclonal antibody Insulin-Like Growth Factor 1 Receptor ( IGF-1R ) . Preclinical clinical data indicate CP 751,871 augments anti-tumor activity chemotherapy . This study identify Maximal Tolerated Dose CP 751,871 ( Maximal Feasible Dose ) combination standard gemcitabine-cisplatin chemotherapy treatment advance Non-Small Cell Lung cancer .</brief_summary>
	<brief_title>Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Na√Øve Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically proven diagnosis Stage IIIB ( N3 and/or T4 ) Stage IV NonSmall Cell Lung Cancer patient 18yearold old , Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 amenable curative surgery radiation therapy adequate organ function ( bone marrow , hepatic , renal , cardiac ) within 14 day prior enrollment . Any prior treatment NonSmall Cell Lung Cancer include chemotherapy , biologic response modifier therapy investigational agent . Patients know brain metastasis , spinal cord compression , uncontrolled superior vein cava syndrome carcinomatous meningitis . Patients gastrointestinal abnormality include active gastrointestinal bleeding , prediabetes ( prefasting glycemia &gt; 120 g/dL and/or glycosylate haemoglobin level &gt; 7.5 % ) , know HIV AIDSrelated illness , significant active cardiac disease receive chronic steroid therapy concurrent use growth hormone growth hormone inhibitor aminoglycoside antibiotic exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>